James M Karis, CEO

James M Karis holds a B.S. in Management and Economics, Purdue University, M.A. in Applied Economics, The American University. He has had a 30-year career in the pharmaceutical, healthcare services, technology and medical device industries. In addition to his experience as an entrepreneur and a Board member, he has held a variety of senior executive positions in public and private companies. From 2000 until 2009 he was President, CEO and Director of Entelos, Inc., a US-based life sciences company. Prior to joining Entelos, he held senior positions in the contract research industry, serving as Chief Operating Officer and President of Parexel International, and as Chief Operating Officer of Pharmaco International. Earlier, he was the Vice President of international operations for Baxter International and is the founder of KMR Group Inc., the leading pharmaceutical R&D analytics firm.

George D. Lundberg, MD, Editor-In-Chief and Chair of the Editorial Advisory Board

In addition to serving as Editor-In-Chief for CollabRx, Dr. Lundberg is President and Chair of the Board of Directors of The Lundberg Institute, a Consulting Professor, Stanford University, and Editor at Large for MedPage Today from Everyday Health. Dr. Lundberg has had thirty years combined experience as Editor in Chief of JAMA (The Journal of the American Medical Association), 10 AMA specialty journals, AMA News, Medscape, The Medscape Journal and e-Medicine from Web MD. A 1995 "pioneer" of the medical internet, Dr. Lundberg was born in Florida, grew up in rural southern Alabama and holds earned and honorary degrees from North Park College, Baylor University, the University of Alabama (Birmingham and Tuscaloosa), the State University of New York, Syracuse, Thomas Jefferson University and the Medical College of Ohio. He completed a clinical internship in Hawaii and a pathology residency in San Antonio. He served in the US Army during the Vietnam War in San Francisco and El Paso, leaving as a lieutenant colonel after 11 years. Dr. Lundberg was then Professor of Pathology and Associate Director of Laboratories at the Los Angeles County/USC Medical Center for 10 years, and for five years was Professor and Chair of Pathology at the University of California, Davis. Dr. Lundberg has worked in tropical medicine in Central America and Forensic Medicine in New York, Sweden and England. His major professional interests are toxicology, violence, communication, physician behavior, patient safety, and health system reform. He is also a past President of the American Society of Clinical Pathologists. He is a frequent lecturer, radio and television guest, and a member of the Institute of Medicine of the National Academy of Sciences, In 2000, the Industry Standard dubbed Dr. Lundberg "Online Health Care's Medicine Man".

Jeff Shrager, PhD, Chief Technology Officer

Jeff Shrager is the CTO of CollabRx, and a consulting associate professor in the Symbolic Systems program at Stanford University. As a computational psychologist of science, Dr. Shrager seeks to understand how science works, and to build human-computer networks that facilitate discovery. Previously, Dr. Shrager co-founded several scientific-computing start-ups (including Afferent Systems, acquired by MDL), and invented BioBike, a web-based biological knowledge platform enabling biologists to develop, run, and share complex analyses of genomic information. Dr. Shrager holds degrees in computer science and cognitive neuroscience from The University of Pennsylvania and CMU, and publishes extensively in scientific computing, AI, biology, genomics, and the cognitive sciences.

Smruti Vidwans, PhD, Chief Scientist

Dr. Vidwans holds a PhD in Genetics and Developmental Biology from the University of California, San Francisco, and an S.B. in Biology from the Massachusetts Institute of Technology. She also brings extensive industry and academic experience in R&D strategy, early stage drug discovery, business development, and strategy and program management. She has consulted with a wide range of pharmaceutical companies, including Pfizer, GlaxoSmithKline, Roche Biosciences, Wyeth, Schering-Plough, on business strategy development, implementation and change management. She worked with McKinsey & Company where she was a key contributor to their Healthcare practice. She has also consulted with non-profits including the Institute for OneWorld Health and several startups in the drug discovery space. Dr. Vidwans was adjudged amongst the top 100 young investigators under 35 for her work on Tuberculosis drug discovery.

Gavin J. Gordon, MBA, PhD, Vice President, Business Development

Prior to joining CollabRx, Dr. Gordon was an Assistant Professor at Harvard Medical School and the Co-Director of the Thoracic Surgery Oncology Laboratory at Brigham and Women’s Hospital in Boston, MA. Dr. Gordon also held an academic appointment in the Dana-Farber/Harvard Cancer Center. At Harvard Medical School, Dr. Gordon directed a translational research laboratory in oncology focused on the generation, validation, and rapid commercialization of patented clinical diagnostic and predictive tests for cancer. His area of expertise is cancer-related therapies, medical devices, and molecular diagnostics. He has experience conducting technological (healthcare/biotech/pharmaceutical/medical device space) and commercial due diligence, valuation, and financial modeling. He has also consulted leading companies on strategies for systems reengineering, streamlining of operations, and maximizing profitability and revenue.

Jay M. Tenenbaum, PhD, Chairman

Jay M. ("Marty") Tenenbaum is co-founder and Chairman of The Board. Dr. Tenenbaum brings to CollabRx the unique perspective of a world-renowned Internet commerce pioneer and visionary. He was founder and CEO of Enterprise Integration Technologies, the first company to conduct a commercial Internet transaction (1992), secure Web transaction (1993) and Internet auction (1993). In 1994, he founded CommerceNet to accelerate business use of the Internet. In 1997, he co-founded Veo Systems, the company that pioneered the use of XML for automating business-to-business transactions. Dr. Tenenbaum joined Commerce One in January 1999, when it acquired Veo Systems. As Chief Scientist, he was instrumental in shaping the company's business and technology strategies for the Global Trading Web. Post Commerce One, Dr. Tenenbaum was an officer and director of Webify Solutions, which was sold to IBM in 2006, and Medstory, which was sold to Microsoft in 2007. Earlier in his career, Dr. Tenenbaum was a prominent AI researcher and led AI research groups at SRI International and Schlumberger Ltd. Dr. Tenenbaum is a fellow and former board member of the American Association for Artificial Intelligence, and a former consulting professor of Computer Science at Stanford. He currently serves as a director of Efficient Finance, Patients Like Me, and the Public Library of Science, and is a consulting professor of Information Technology at Carnegie Mellon's new West Coast campus. Dr. Tenenbaum holds B.S. and M.S. degrees in Electrical Engineering from MIT, and a PhD from Stanford.

James M Karis, CEO

James M Karis holds a B.S. in Management and Economics, Purdue University, M.A. in Applied Economics, The American University. He has had a 30-year career in the pharmaceutical, healthcare services, technology and medical device industries. In addition to his experience as an entrepreneur and a Board member, he has held a variety of senior executive positions in public and private companies. From 2000 until 2009 he was President, CEO and Director of Entelos, Inc., a US-based life sciences company. Prior to joining Entelos, he held senior positions in the contract research industry, serving as Chief Operating Officer and President of Parexel International, and as Chief Operating Officer of Pharmaco International. Earlier, he was the Vice President of international operations for Baxter International and is the founder of KMR Group Inc., the leading pharmaceutical R&D analytics firm.

Rob Rodin, Director

Rob Rodin is the Chairman and CEO of RDN Group; strategic advisors focused on corporate transitions, customer interface, sales and marketing, distribution and supply chain management. (Customers include: GM, GE, US Navy, Avnet, Siemens, Simon and Schuster). Additionally, he serves as Vice Chairman, Executive Director and Chairman of the Investment Committee of CommerceNet which researches and funds open platform, interoperable business services to advance commerce. Mr. Rodin served for over 10 years as CEO and President of Marshall Industries (NYSE: MI) a global, industrial, electronics distributor and supply chain management company with over $2 billion in sales. Information Week Magazine highlighted Marshall Industries as the "World's Number One Company in the Use of Technology", and CIO Magazine recognized Mr. Rodin as one of the "Top 100 Leaders for the New Millennium". UCLA presented Mr. Rodin with the "Information Systems Award for System Leadership" and the University of Connecticut presented him with the "Distinguished Alumni Award" and elected him to the "University Hall of Fame". Mr. Rodin's best selling book, "Free, Perfect and Now: Connecting to the Three Insatiable Customer Demands", chronicles the radical transformation of Marshall Industries. The changes he led have been taught as case studies at Harvard Business School, Columbia University, USC, MIT, and Stanford University. Mr. Rodin’s Board activities include: the Board of Directors of Napster (NAPS)(formally Roxio) as Chairman of the Compensation Committee and a Member of the Audit Committee, Vice Chairman of the Board of Directors of CommerceNet, Board Member / Director of supplyFX, Board Member / Director of ALS Therapy Development Institute, Board Member / Director and Member of the Governance and Nominating Committee of SM&A (NASDQ: WINS), Director of Inter-tel (NASDAQ: INTL), Advisory Board of LASEC (Los Angeles Sports and Entertainment Commission), Advisory Board of Electronics Supply & Manufacturing Magazine (CMP Publications), on the planning committee for Harvard and Stanford Presidents Seminars (YPO) and on University of Connecticut's School of Business Board of Advisors (Executive Council and Strategic Development Committee) as well as several private company advisory boards. Mr. Rodin formerly served on the Advisory Board of Distribution at USC, the Board of Directors of RosettaNet, as a Trustee of the W. Edwards Deming Institute, and President of NEDA’s (National Electronic Distribution Association) Education Foundation.

Barry Newman, PhD, Director

Barry Newman is a Venture Partner at NeoCarta Ventures. Mr. Newman has had a distinguished investment banking career which included: Vice Chairman of the Technology Group at Bear Stearns, the Head of Global Technology Corporate and Investment Banking for Banc of America Securities and its predecessor Nationsbanc Montgomery Securities, and head of Global Technology Corporate finance at Salomon Brothers and Salomon Smith Barney. Mr. Newman was a founder and served as CFO of Anthem Partners, a boutique merchant bank. Mr. Newman was also a principal at Odyssey Partners, a private equity and hedge fund organization and has served as CEO and CFO of several financial services and manufacturing organizations. Mr. Newman is a member of the MIT Visiting Committee on Student Life, the MIT Corporation Development Committee and the Dean's Strategic Council of the Stanford Law School. Mr. Newman holds Bachelor of Science degrees in both Chemical Engineering and Life Sciences from MIT, MBA and JD degrees from Stanford University and a Master of Laws (Taxation) from NYU.

Donald Kennedy, PhD, Chairman

Donald Kennedy is President Emeritus and Bing Professor of Environmental Science and Policy, Emeritus at Stanford University. He is also a Senior Fellow of the Freeman-Spogli Institute for International Studies and the Wood Institute for the Environment, and is a member of the Food Security and Environment Program in both Institutes. Dr. Kennedy was editor-in-chief of Science (2000-2008) and also served as Commissioner of the US Food and Drug Administration during the Carter administration. Dr. Kennedy is a member of the National Academy of Sciences, the American Academy of Arts and Sciences, and the American Philosophical Society. He served on the National Commission for Public Service and the Carnegie Commission on Science, Technology and Government, and is a founding director of the Health Effects Institute. He currently serves as a director of the Carnegie Endowment for International Peace, and as co-chair of the National Academies’ Project on Science, Technology and Law. Dr. Kennedy received A.B. and PhD degrees in biology from Harvard University.

Lee Hartwell, PhD

Lee Hartwell has been president and director of the Fred Hutchinson Cancer Research Center since 1997. Dr. Hartwell is the recipient of many national and international scientific awards, including the 2001 Nobel Prize in Physiology or Medicine for his work in yeast genetics. Other honors include the Albert Lasker Basic Medical Research Award, the Gairdner Foundation International Award and the Alfred P. Sloan Award in cancer research. Dr. Hartwell became professor of genetics at the University of Washington in 1973, where he joined the faculty in 1968. He was an assistant professor at the University of California, Irvine from 1965 to 1968. Dr. Hartwell engaged in postdoctoral work at the Salk Institute for Biological Studies from 1964 through 1965 with Dr. Renato Dulbecco. He is also a member of the National Academy of Sciences. Dr. Hartwell holds a B.S. degree from the California Institute of Technology and a PhD Degree from the Massachusetts Institute of Technology under the mentorship of Dr. Boris Magasanik.

David G. Nathan, MD

David Nathan is President Emeritus of Dana-Farber Cancer Institute, which provides patient care in addition to conducting research. He was president of DFCI from 1995 to 2000. Dr. Nathan chaired the Department of Pediatrics and served as physician-in-chief of Children’s Hospital in Boston from 1985 to 1995. He was chief of hematology and oncology at CHB and DFCI after serving as chief of hematology at CHB between 1967 and 1984. Dr. Nathan was senior resident in medicine at the then Peter Bent Brigham Hospital and clinical associate at the National Cancer Institute from 1959 to 1966. His textbook, titled Hematology of Infancy and Childhood, is the leading text in the field. He is the author of two popular books: Genes, Blood and Courage and The Cancer Treatment Revolution: How Smart Drugs and Other New Therapies Are Renewing Our Hope and Changing the Face of Medicine. Dr. Nathan is a member of the American Society for Clinical Investigation, the Association of American Physicians, the American Pediatric Society, the Institute of Medicine, the American Academy of Arts and Sciences and the American Philosophical Society. He is the recipient of numerous awards, including the National Medal of Science, the Stratton medal of the American Society of Hematology, the Walker Prize of the Boston Museum of Science, the John Howland Medal of the American Pediatric Society, and the George M. Kober Medal of the Association of American Physicians. He is one of only three physicians to receive both the Howland and Kober medals.